Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.

@article{Knoll2016RamiprilVP,
  title={Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.},
  author={Greg A. Knoll and Dean Fergusson and Micha{\"e}l Chass{\'e} and Paul C. H{\'e}bert and George A Wells and Lee Anne Tibbles and Darin J. Treleaven and David V Holland and Christine A. White and N Orman Muirhead and Marcelo Cantarovich and Michel R. P{\^a}quet and Bryce A. Kiberd and Sita M Gourishankar and Jean Shapiro and Ramesh Prasad and Edward Howard Cole and Helen Pilmore and Valerie Cronin and Debora L Hogan and Tim Ramsay and John S. Gill},
  journal={The lancet. Diabetes & endocrinology},
  year={2016},
  volume={4 4},
  pages={
          318-26
        }
}
BACKGROUND Angiotensin-converting enzyme inhibitors have been shown to reduce the risk of end-stage renal disease and death in non-transplant patients with proteinuria. We examined whether ramipril would have a similar beneficial effect on important clinical outcomes in kidney transplant recipients with proteinuria. METHODS In this double-blind, placebo-controlled, randomised trial, conducted at 14 centres in Canada and New Zealand, we enrolled adult renal transplant recipients at least 3… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.

  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Similar Papers

Loading similar papers…